Skip to main content

Drug Interactions between Alphagan and tapentadol

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

brimonidine ophthalmic tapentadol

Applies to: Alphagan (brimonidine ophthalmic) and tapentadol

After using brimonidine ophthalmic, some of the medication may be absorbed into the bloodstream and occasionally produce central nervous system side effects such as dizziness, drowsiness, and difficulty concentrating. Combining it with tapentadol or other medications that can also have these effects may increase the risk. You should avoid or limit the use of alcohol while being treated with these medications. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.

Drug and food/lifestyle interactions

Major

tapentadol food/lifestyle

Applies to: tapentadol

Consumer information for this interaction is not currently available.

GENERALLY AVOID: Alcohol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics including tapentadol. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.

GENERALLY AVOID: Consumption of alcohol while taking extended-release formulations of tapentadol may cause rapid release of the drug, resulting in high systemic levels of tapentadol that may be potentially lethal even in opioid-tolerant patients. Alcohol appears to disrupt the extended-release mechanism, causing 'dose-dumping' into the bloodstream. A clinical study evaluated healthy volunteers administered a single dose of extended-release tapentadol (100 mg or 250 mg) with 240 mL of 40% alcohol. The mean peak tapentadol concentration (Cmax) was 48% higher when alcohol was combined with the 100 mg dose and 28% higher when alcohol was combined with the 250 mg dose, as compared to control. Additionally, the systemic exposure (AUC) of tapentadol increased by 16-17% when combined with alcohol.

MANAGEMENT: Patients taking extended-release formulations of tapentadol should not consume alcohol or use medications that contain alcohol. In general, narcotics such as tapentadol should not be combined with alcohol. Modified and/or extended-release tapentadol formulations must also be swallowed whole and not crushed, chewed or divided.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer